User profiles for Y. H. Park

Young Ho Park

Korea National University of Transportation
Verified email at ut.ac.kr
Cited by 1067

A review on MXene synthesis, stability, and photocatalytic applications

…, YH Park, JH Lee, J Rawal, SY Lee, I In, SJ Park - ACS …, 2022 - ACS Publications
Photocatalytic water splitting, CO 2 reduction, and pollutant degradation have emerged as
promising strategies to remedy the existing environmental and energy crises. However, …

Inter- and intraspecific phylogenetic analysis of the genus Nocardioides and related taxa based on 16S rDNA sequences

JH Yoon, ST Lee, YH Park - International Journal of …, 1998 - microbiologyresearch.org
The 16S rDNAs from 38 strains of the genus Nocardioides, two Aeromicrobium species and
Terrabacter tumescens were directly sequenced and then analysed. The mean nucleotide …

Identification of Saccharomonospora Strains by the Use of Genomic DNA Fragments and rRNA Gene Probes

…, ST Lee, M Goodfellow, YH Park - … of Systematic and …, 1996 - microbiologyresearch.org
Restriction digestion fragments of DNAs extracted from 14 representative strains of
Saccharomonospora azurea, “Saccharomonospora caesia,” Saccharomonospora cyanea, …

Antimicrobial effects of silver nanoparticles

…, SJ Park, HJ Lee, SH Kim, YK Park, YH Park… - … , biology and medicine, 2007 - Elsevier
The antimicrobial effects of silver (Ag) ion or salts are well known, but the effects of Ag
nanoparticles on microorganisms and antimicrobial mechanism have not been revealed clearly. …

[HTML][HTML] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer

…, YS Chae, KS Lee, N Niikura, YH Park… - … England Journal of …, 2022 - Mass Medical Soc
Background Among breast cancers without human epidermal growth factor receptor 2 (HER2)
amplification, overexpression, or both, a large proportion express low levels of HER2 that …

[HTML][HTML] Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer

…, SB Kim, WP Chung, SA Im, YH Park… - … England Journal of …, 2022 - Mass Medical Soc
Background Trastuzumab emtansine is the current standard treatment for patients with
human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose …

[HTML][HTML] Event-free survival with pembrolizumab in early triple-negative breast cancer

…, S Kümmel, J Bergh, C Denkert, YH Park… - … England Journal of …, 2022 - Mass Medical Soc
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …

Antibacterial Activity and Mechanism of Action of the Silver Ion in Staphylococcus aureus and Escherichia coli

…, KW Kim, S Shin, SH Kim, YH Park - Applied and …, 2008 - Am Soc Microbiol
The antibacterial effect and mechanism of action of a silver ion solution that was electrically
generated were investigated for Staphylococcus aureus and Escherichia coli by analyzing …

[HTML][HTML] Pembrolizumab for early triple-negative breast cancer

…, S Kümmel, J Bergh, C Denkert, YH Park… - … England Journal of …, 2020 - Mass Medical Soc
Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer. …

[HTML][HTML] Intravascular imaging–guided or angiography-guided complex PCI

…, HS Ahn, CW Nam, HJ Yoon, YH Park… - … England Journal of …, 2023 - Mass Medical Soc
Background Data regarding clinical outcomes after intravascular imaging–guided percutaneous
coronary intervention (PCI) for complex coronary-artery lesions, as compared with …